Pipeline VP-102
Verricaʼs lead product candidate, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. On July 21, 2023, Verrica’s lead product, YCANTH® (cantharidin) topical solution 0.7%, became the first treatment approved by the FDA to treat adult and pediatric patients as young as two years of age with molluscum contagiosum. Verrica is currently focusing our efforts on the commercialization of YCANTH (VP-102) for the treatment of molluscum and the development of YCANTH (VP-102) for the treatment of common warts. We are currently not advancing the development of VP-102 for the treatment of external genital warts.
- PRE-IND
- Phase 1
- Phase 2
- Phase 3
- NDA
-
Next Expected
Milestone
COMMERCIALIZED
Type C minutes received from FDA; Sought concurrence from FDA and Phase 3 trial could begin as early as mid-2025*
No plans underway to begin Phase 3 trial.
*Type C meeting held with FDA on clinical development plan for YCANTH's (VP-102) Common Warts indication on November 6, 2023. Meeting resulted in gaining alignment on the design of a pivotal Phase 3 development plan to evaluate YCANTH for the treatment of Common Warts. We sought additional guidance from the FDA in the second half of 2024 and anticipate Phase 3 trial could begin as early as mid-2025.
We retain exclusive royalty-free rights to YCANTH (VP-102) across all indications globally
Common Warts
Common warts (verruca vulgaris) are contagious skin growths caused by a human papilloma virus (HPV). They represent one of the largest unmet needs in dermatology, with approximately 22 million cases in the United States. There are no FDA-approved treatments for common warts, which can be difficult to treat and negatively affect quality of life. Verrica has announced positive top-line results from its COVE-1 Phase 2 open-label clinical study of VP-102 for the treatment of common warts.
External Genital Warts
External genital warts are a viral skin disease caused by a human papilloma virus (HPV), which forms lesions on the surface of the skin on or near the genitals. HPV is the most common sexually transmitted infection in the United States. Verrica has announced positive top-line results from its CARE-1 Phase 2 study and intends to conduct additional studies of VP-102 for the treatment of external genital warts.
